Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
4xgJ0jLvBSs1nnA1
